Celcuity LLCCELC
▼ NegativeCapitalrelevance
Q2 GAAP EPS miss of $0.28 and increased operating expenses.
Impact on assets 1
Biotech & Genomic Medicine
Celcuity LLCCelcuity Q2 GAAP EPS misses by $0.28
2▲0 ▼1Impact / 5
Celcuity reported a second-quarter 2026 GAAP loss of $1.44 per share, missing expectations by $0.28. Total operating expenses rose to $66.1 million from $44.0 million a year earlier, driven by a $27.4 million increase in selling, general and administrative expenses to $35.0 million as the company ramped up commercial launch activities for REVTORPYK. Research and development expenses fell to $31.1 million from $36.4 million, primarily due to lower clinical trial costs for the VIKTORIA-1 Phase 3 trial and reduced license milestone costs. Net cash used in operating activities was $55.4 million, and the company ended the quarter with $754.0 million in cash, cash equivalents and short-term investments, which it expects will fund operations at least into 2029.
Celcuity LLCQ2 GAAP EPS miss of $0.28 and increased operating expenses.